EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of Non-invasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance

Andriana Nikolova, Sean Agbor-Enoh, Saskia Bos, Marisa Crespo-Leiro, Stephan Ensminger, Marta Jimenez-Blanco, Annamaria Minervini, Michael Perch, Javier Segovia, Robin Vos, Kiran Khush, Luciano Potena

Transplant International · 11.06.2024 · 37

DOI: 10.3389/ti.2024.12445 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant International, online erschienen am 11.06.2024. Verfasst von Andriana Nikolova und 11 weiteren Autor:innen. Beteiligte Einrichtung: Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States. Hauptthemen laut MEDLINE: Biomarkers, Graft Rejection, Heart Transplantation, Lung Transplantation. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While allograft rejection (AR) continues to threaten the success of cardiothoracic transplantation, lack of accurate and repeatable surveillance tools to diagnose AR is a major unmet need in the clinical management of cardiothoracic transplant recipients. Endomyocardial biopsy (EMB) and transbronchial biopsy (TBBx) have been the cornerstone of rejection monitoring since the field’s incipience, but both suffer from significant limitations, including poor concordance of biopsy interpretation among pathologists. In recent years, novel molecular tools for AR monitoring have emerged and their performance characteristics have been evaluated in multiple studies. An international working group convened by ESOT has reviewed the existing literature and provides a series of recommendations to guide the use of these biomarkers in clinical practice. While acknowledging some caveats, the group recognized that Gene-expression profiling and donor-derived cell-free DNA (dd-cfDNA) may be used to rule out rejection in heart transplant recipients, but they are not recommended for cardiac allograft vasculopathy screening. Other traditional biomarkers (NT-proBNP, BNP or troponin) do not have sufficient evidence to support their use to diagnose AR. Regarding lung transplant, dd-cfDNA could be used to rule out clinical rejection and infection, but its use to monitor treatment response is not recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersGraft RejectionHeart TransplantationLung TransplantationHumansBiopsyCell-Free Nucleic AcidsEuropeGene Expression ProfilingSocieties, Medical

Stichwörter der Autor:innen

biomarkerguidelinesheart transplantationlung transplantrejection

Substanzen

BiomarkersCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
  • Genomic Research Alliance for Transplantation (GRAfT) and Laboratory of Applied Precision Omics, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, United States.
  • Lung Transplantation, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, United States.
  • Newcastle University Translational and Clinical Research Institute, Newcastle uponTyne, United Kingdom.
  • Institute of Transplantation, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle uponTyne, United Kingdom.
  • Cardiology Department, Complexo Hospitalario Universitario A Coruna (CHUAC), Instituto de Investigación Biomédica A Coruña (INIBIC), Universitade de Coruna (UDC), Centro de Investigación Biomédica en Red-Enfermedades Ca…

Zitieren

APA

Nikolova, A., Agbor-Enoh, S., Bos, S., Crespo-Leiro, M., Ensminger, S., Jimenez-Blanco, M., Minervini, A., Perch, M., Segovia, J., Vos, R., Khush, K., & Potena, L. (2024). European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of Non-invasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance. Transplant International, 37. https://doi.org/10.3389/ti.2024.12445

Vancouver

Nikolova A, Agbor-Enoh S, Bos S, Crespo-Leiro M, Ensminger S, Jimenez-Blanco M, et al. European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of Non-invasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance. Transplant International. 2024;37. doi:10.3389/ti.2024.12445

BibTeX
@article{Nikolova2024,
  author = {Nikolova, Andriana and Agbor-Enoh, Sean and Bos, Saskia and Crespo-Leiro, Marisa and Ensminger, Stephan and Jimenez-Blanco, Marta and Minervini, Annamaria and Perch, Michael and Segovia, Javier and Vos, Robin and Khush, Kiran and Potena, Luciano},
  title = {European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of Non-invasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance},
  journal = {Transplant International},
  year = {2024},
  volume = {37},
  doi = {10.3389/ti.2024.12445}
}
Kostenlos starten →